

In the claims:

B<sub>2</sub>  
sub C<sub>1</sub>  
1. (amended) An isolated peptide comprising the amino acid sequence defined under SEQ ID NO: 1 or amino acid sequence derived therefrom by deletion, substitution or insertion of 1 to 5 amino acid residues, a precursor thereof, or a salt of said peptide, wherein the peptide does not comprise the amino acid sequence of SEQ ID NO: 31 or SEQ ID NO: 32.

sub C<sub>2</sub>  
6. (amended) An isolated peptide having the amino acid sequence defined under any of SEQ ID NO: 35 through SEQ ID NO: 55, a precursor thereof, or a salt of said peptide.

B<sub>4</sub>  
8. (amended) A peptide or precursor as claimed in Claim 1 which has cortistatin or somatostatin activity.

B<sub>5</sub>  
20. (amended) A pharmaceutical composition as claimed in Claim 18 which is an agent for the treatment or prevention of hormone producing tumors, acromegaly, gigantism, dementia or gastric ulcer, a hormone secretion inhibitor, a tumor growth inhibitor, or a neural activity or sleep modulator.

REMARKS

In the above referenced application, Claims 1-8, 18, 20 and 24 are pending in the above referenced application and stand rejected. Claims 1, 6, 8 and 20 have been amended to more particularly set forth and distinctly claim the present invention. In addition, the specification has been amended to refer to earlier filed applications. Support for the amendments is found throughout the specification. In light of the above amendments and following discussion, Applicant respectfully requests that the outstanding rejections be withdrawn and the claims be allowed.